Skip to main content
An official website of the United States government
Email

CTEP IP Option and Collaborative Agreements

A diverse group of professionals celebrate a successful business deal with handshakes and smiles..

The Cancer Therapy Evaluation Program (CTEP)’s primary mission is to make promising new cancer treatments available to patients as quickly and as safely as possible. CTEP collaborates with clinicians, researchers, and industry to co-develop novel anti-cancer agents through Cooperative Research and Development Agreements (CRADAs). CTEP sponsors Investigational New Drug applications for clinical evaluation of new agents and assumes regulatory responsibility for CTEP-sponsored clinical trials. Investigators receive access to these promising novel agents in their clinical trials, and industry partners benefit from CTEP resources, expertise, and opportunities to evaluate agents in a wide range of cancer types and treatment settings.

CTEP-IND agents under a current CRADA may be requested by investigators for use in clinical and non-clinical research.

Intellectual Property and the CTEP IP Option

CTEP’s policy on intellectual property agreements with funding recipients, called the IP Option, is designed to provide incentives and assurances for Collaborators and Institutions to participate in CTEP-sponsored clinical studies, by granting options to intellectual property rights for inventions arising from trials of CTEP-IND agents.

Model Agreements

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “CTEP IP Option and Collaborative Agreements was originally published by the National Cancer Institute.”

Email